Zepbound may not be as widely known as its competitors, but the weight-loss drug may soon be more accessible than the rest.

The excess payments Medicare Advantage plans receive for higher risk scores may be more influenced by differences in coding practices rather than actual differences in disease burden between MA and ...

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...

Medicare, the government-backed program for adults aged 65 and older and those with disabilities, only covers the use of ...

United Health Group, the largest U.S. health insurer by enrollees, was under pressure after Sen. Chuck Grassley, chairman of the Senate Judiciary Committee, sent the conglomerate's chief executive, ...

Coverage complications are not unusual in the U.S. healthcare system. But the challenge is magnified for these obesity ...

Wave goodbye to the Part D "donut hole" and hello to a $2,000 cap on the amount you'll pay for medications. But other changes ...

It’s time to treat obesity as a chronic disease and have Medicare cover these life-changing AOMs. By taking action now, we ...

Compared to other diabetes medications, GLP-1 drugs like Ozempic were associated with a lower risk for depression in a recent ...

Opinion: It’s time we prioritize innovation and invest in solutions that truly address the root cause of this chronic and ...

Eli Lilly is offering higher-dose vials through its direct-to-consumer website, LillyDirect, which started offering lower ...

Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a five-year period and could ...